Conclusion
DISEASE PROGRESSION, RECURRENCE, METASTATIC DISEASE
In conclusion, FT in PCa using HIFU demonstrated good functional results in patients. However, HIFU was not as safe oncologically as expected, with recurrence and progression rates of 37.93% and risk of disease progression to metastatic disease. We strongly support the further scientific evaluation of FT, but until oncological risks cannot be safely reduced, we no longer recommend HIFU treatment in our department at this time.